亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes

志愿者 抗体 医学 相(物质) 免疫学 生物 化学 农学 有机化学
作者
François Philippe,Philippe Couttet,И. Ф. Демин,Birgit Jaitner,Yinuo Pang,Ronenn Roubenoff,Esther Sutter,Yoav E. Timsit,Marie Anne Valentin,Beate Vogel,G. Woerly,Armin Wolf,Ursula Schramm
出处
期刊:Journal of Pharmacology and Experimental Therapeutics [American Society for Pharmacology & Experimental Therapeutics]
卷期号:369 (3): 428-442 被引量:11
标识
DOI:10.1124/jpet.118.254128
摘要

The colony-stimulating factor-1 (CSF-1) receptor pathway has been implicated in a variety of diseases, and CSF-1-dependent mechanisms are also involved in bloodborne protein clearance. Lacnotuzumab is a novel, high-affinity, humanized, anti-CSF-1 monoclonal antibody that prevents CSF-1-mediated receptor activation. This phase 1, two-part, double-blind study in healthy volunteers assessed the safety and tolerability of lacnotuzumab and its pharmacokinetics (PK) and pharmacodynamic properties. Part A (n = 36) was a single, ascending-dose assessment of eight lacnotuzumab doses (0.01-20 mg/kg); in part B (n = 16), lacnotuzumab was administered at either 5 or 10 mg/kg. In each study cohort, individuals were randomized 3:1 to lacnotuzumab or placebo. Lacnotuzumab was generally well tolerated. At higher doses (10 and 20 mg/kg), creatine kinase (CK) elevations (>5× the upper limit of normal, but asymptomatic and reversible) and mild transient periorbital swelling were reported. Most adverse events (AEs) were low-grade, no unexpected or novel AEs were observed, and there were no discontinuations for AEs. Free, unbound lacnotuzumab serum concentration-time profiles showed nonlinear PK across doses from 0.01 to 20 mg/kg, with faster apparent elimination at lower doses or concentrations; this finding was consistent with apparent target-mediated drug disposition. Lacnotuzumab also showed dose-dependent, on-target effects on multiple downstream biomarkers. Preclinical investigations of the CK elevation and periorbital swelling observed after lacnotuzumab administration suggest that these are reversible, nonpathological events linked to inhibition of the CSF-1 pathway. These data support further evaluation of lacnotuzumab in clinical studies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
在水一方应助落伍少年采纳,获得10
18秒前
威武吴完成签到,获得积分10
18秒前
sinyipyeung完成签到,获得积分20
20秒前
田様应助香妃采纳,获得10
51秒前
乐乐应助香妃采纳,获得10
51秒前
55秒前
小球完成签到,获得积分10
1分钟前
RyanNeo应助科研通管家采纳,获得10
1分钟前
moxin完成签到,获得积分10
1分钟前
1分钟前
星河发布了新的文献求助10
1分钟前
1分钟前
2分钟前
852应助星河采纳,获得20
2分钟前
吕懿发布了新的文献求助10
2分钟前
星河完成签到,获得积分20
2分钟前
魏笑白完成签到 ,获得积分10
2分钟前
2分钟前
rocky15应助小高采纳,获得10
3分钟前
快来帮帮我完成签到,获得积分10
3分钟前
3分钟前
wangayting发布了新的文献求助200
3分钟前
白云朵儿完成签到,获得积分10
4分钟前
wangayting完成签到,获得积分10
4分钟前
追三完成签到 ,获得积分10
4分钟前
rocky15应助messi采纳,获得200
4分钟前
4分钟前
李健的小迷弟应助phentjn采纳,获得10
5分钟前
尊敬曼岚发布了新的文献求助10
5分钟前
科目三应助害羞的紫伊采纳,获得10
5分钟前
5分钟前
落伍少年发布了新的文献求助10
6分钟前
落伍少年完成签到,获得积分10
6分钟前
6分钟前
快递乱跑完成签到 ,获得积分10
6分钟前
6分钟前
6分钟前
尊敬曼岚完成签到,获得积分20
6分钟前
吕懿发布了新的文献求助10
6分钟前
rocky15应助messi采纳,获得10
6分钟前
高分求助中
Un calendrier babylonien des travaux, des signes et des mois: Séries iqqur îpuš 1036
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
行動データの計算論モデリング 強化学習モデルを例として 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2545467
求助须知:如何正确求助?哪些是违规求助? 2175634
关于积分的说明 5600159
捐赠科研通 1896337
什么是DOI,文献DOI怎么找? 946226
版权声明 565355
科研通“疑难数据库(出版商)”最低求助积分说明 503552